Abstracts tagged "Outcome measures"

Abstract Number: 2536 • 2013 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index
Hervé Devilliers^1,2, Mark Kosinski³, Cindy Garris⁴ and Meenakshi Jolly⁵, ¹Clinical investigation and clinical epidemiology center (INSERM CIE01), Dijon, France, ²Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ³QualityMetric Inc, Lincoln, RI, ⁴US Health Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…
Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting
A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Chan-Bum Choi^3,4, Soyoung Won⁵, So-Young Bang⁶, Hoon-Suk Cha⁷, Jung-Yoon Choe⁸, Won Tae Chung⁹, Seung-Jae Hong¹⁰, Jae-Bum Jun⁴, Hyoun Ah Kim¹¹, Jinseok Kim¹², Seong-Kyu Kim⁸, Tae-Hwan Kim⁴, Hye-Soon Lee¹³, Jaejoon Lee⁷, Jisoo Lee¹⁴, Shin-Seok Lee¹⁵, Sung Won Lee¹⁶, Yeon-Ah Lee¹⁰, Seong-Su Nah¹⁷, Chang-Hee Suh¹⁸, Dae-Hyun Yoo⁴, Bo Young Yoon¹⁹ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Hanyang University Guri Hospital, Guri, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ¹¹Ajou University Hospital, Suwon, South Korea, ¹²Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, ¹³Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁴Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹⁶Rheumatology, Dong-A University Hospital, Busan, South Korea, ¹⁷Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, ¹⁸Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁹Inje University Ilsan Paik Hospital, Goyang, South Korea
Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…
Abstract Number: 2292 • 2013 ACR/ARHP Annual Meeting
Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Edward C. Keystone^3,4, Xiuying Li⁵, J. Carter Thorne⁶ and Claire Bombardier⁷, ¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁴University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, ⁵Clinical Decision Making and Health Care, University Health Network, Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in Rheumatoid Arthritis (RA) can adversely affect therapeutic decisions. The pattern of PGA and MDGA,…
Abstract Number: 1264 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients
Julia G. Harris^1,2, Kristyn I. Maletta³, Evelyn M. Kuhn³ and Judyann C. Olson^1,2, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³National Outcomes Center, Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually every organ system and may lead to significant morbidities. A…
Abstract Number: 2300 • 2013 ACR/ARHP Annual Meeting
Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting
Gary Craig^1,2, Howard Kenney^1,2, Keith Knapp² and Sergio Schwartzman³, ¹Arthritis Northwest PLLC., Spokane, WA, ²T3 JointMan LLC., Spokane, WA, ³Rheumatology, Hosp for Special Surgery, New York, NY
Background/Purpose: The public database JointManTMwas launched January 2012 with a mission to provide a practical outcome tool to manage patients with RA in a clinical…
Abstract Number: 968 • 2013 ACR/ARHP Annual Meeting
Success Of Educational Intervention In Improving The Management Of Rheumatoid Arthritis
Nimish Mehta and Ronald Viggiani, Medscape, LLC, New York, NY
Background/Purpose: In many patients with rheumatoid arthritis (RA), the disease is not adequately controlled and only a minority of patients attain the goal of consistent…
Abstract Number: 2238 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort
Bernard Combe¹, Isabelle Logeart², M. Belkacemi³, S Dadoun⁴, Jean-Pierre Daurès⁵ and Maxime Dougados⁶, ¹Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ²Pfizer, Paris, France, ³CHRU Montpellier, Montpellier, France, ⁴Paris-Pitié Salpêtrière University Hospital, Paris, France, ⁵Service BESPIM, CHU, Nimes, France, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Treat to Target and EULAR recommendations highlighted the need for achieving and maintaining remission in patients with early RA. We investigated if early…
Abstract Number: 763 • 2013 ACR/ARHP Annual Meeting
The Risk Of Myocardial Infarction In Systemic Sclerosis: A Population-Based Cohort Study
Iman Hemmati¹, Hyon K. Choi^2,3, Kamran Shojania^3,4, Eric C. Sayre³ and J. Antonio Avina-Zubieta^3,5, ¹Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: An increased risk of premature atherosclerosis has been well described in patients with rheumatoid arthritis and systemic lupus erythematosus. However, there is limited data…
Abstract Number: 2245 • 2013 ACR/ARHP Annual Meeting
Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Paul R. Fortin³, George A. Tomlinson⁴ and Claire Bombardier^5,6, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Division of rheumatology and Department of Health Policy, Management, and Evaluation, University Health Network, Toronto, ON, Canada
Background/Purpose: Patient reported outcome measures (PROM) are used in routine practice for assessment of disease activity. They have been shown to correlate well with other…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 2247 • 2013 ACR/ARHP Annual Meeting
Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Martin J. Bergman^1,2, Sapna Sangani³, Isabel Castrejón⁴ and Theodore Pincus⁴, ¹Medicine, Drexel University College of Medicine, Philadelphia, PA, ²Taylor Hospital, Ridley Park, PA, ³Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) often report fatigue, but a possible impact of disease on sleep and/or on disease activity are poorly characterized. We…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 2135 • 2013 ACR/ARHP Annual Meeting
Musculoskeletal Pain Explains Differences In Function At Time Of Surgery In Black TKR and THR Patients
Anthony Porter¹, Wenjun Li², Leslie R. Harrold¹, Milagros Rosal³, Philip Noble⁴, David Ayers², Patricia D. Franklin² and Jeroan Allison⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ³Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Baylor College of Medicine, Houston, TX, ⁵Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The existence of racial disparities in total knee (TKR) and total hip (THR) replacement outcomes is well established but not well understood. The burden…
Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 1723 • 2012 ACR/ARHP Annual Meeting
The Development of the Rheumatoid Arthritis Patient Priorities in Pharmacological Intervention Outcome Measures
Tessa Sanderson¹, John R. Kirwan², Marianne Morris¹, Jon Pollock³, Robert Noddings², Anne Watts² and Sarah Hewlett⁴, ¹University of the West of England, Bristol, United Kingdom, ²Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ³Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, ⁴Academic Rheumatology, University of the West of England, Bristol, United Kingdom
Background/Purpose: Previous research developed a set of 8 priority treatment outcomes generated by patients to complement the professionally developed ACR core set for RA. These…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].